Tribulations of a prostate cancer trial – lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial.
From 2004–2009 a total of 226 out of a target of 750 prostate cancer patients have been randomised into the Timing of Androgen Deprivation trial between immediate and delayed androgen deprivation. A screening log was kept by participating centres for the first 928 patients, which documented the reasons for non-entry into the trial; 42.7% of screened patients were ineligible and a further 33.0% were not entered for other reasons. Fewer than 10% of patients cited not wanting to be part of a clinical trial as a reason for non-entry. Strategies to improve recruitment included broadening the eligibility criteria, encouraging international collaboration, the use and support of research nurses in the private health care environment, and the use of phone follow-up. Recruitment will be completed at the number originally intended to inform the interim analysis designed to test the validity of the statistical assumptions, and a combined survival analysis with the Canadian study is planned.
Peter MacCallum Cancer Centre, East Melbourne, and University of Melbourne, Parkville, Australia. gillian.duchesne@petermac.org
Gillian M
GM
Duchesne
Henry H
HH
Woo
Deborah
D
Howell
Mary
M
Kaimakamis
Evan
E
Kemp
D000726:Androgen Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016896:Treatment Outcome; D014739:Victoria
D000726:Androgen Antagonists